BRIGATINIB
brigatinib 30 mg tablet, 28
BRIGATINIB (11980M)
11980M
Manner of administration:Oral
Restriction
Indication: Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer
(NSCLC)
Treatment phase: Continuing treatment
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 4 | Max qty units: 112 | # of repeats: 3 | DPMQ: $6,483.40 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Alunbrig | |||||
